Skip to main content
Premium Trial:

Request an Annual Quote

BGI Bloodstream Pathogen Nucleic Acid Detection Kit Gets CE Mark

NEW YORK – BGI said last week that its nucleic acid detection kit for bloodstream infection pathogens has received the CE mark.

The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, a holding subsidiary of BGI Genomics, uses combinatorial probe-anchor synthesis technology to prepare libraries for metagenomic sequencing to detect pathogens that cause bloodstream infections. It is designed to construct a sequencing library directly from clinical samples.

The sequencing data is analyzed using dedicated software and compared to a curated microbial genome reference database for the detection of pathogens including bacteria, fungi, viruses, and parasites. 

According to Shenzhen, China-based BGI, the kit has already been used widely in clinical practice to identify pathogens causing bloodstream infection.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.